Text Size

Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

This study has been completed.
Sponsor:
Collaborator:
Teva Branded Pharmaceutical Products, R&D Inc.
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT00643578
First received: March 20, 2008
Last updated: November 29, 2011
Last verified: November 2011
History of Changes
Results First Received: August 5, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacodynamics Study;   Intervention Model: Crossover Assignment;   Masking: Open Label
Condition: Asthma
Interventions: Drug: formoterol
Device: Dry Powder Inhaler (Twisthaler)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between April and November, 2008, the UF Asthma Research Lab recruited 37 patients for study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 37 subjects who signed informed consent, 25 did not meet inclusion/exclusion criteria. The provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second (PC20FEV1) was not less than or equal to 4 mg/mL.

Reporting Groups
  Description
Formoterol 12 First a single dose of 12 mcg of formoterol was given first, then 24 mcg of formoterol
Formoterol 24 First a single dose of 24 mcg of formoterol was given first, then 12 mcg of formoterol

Participant Flow:   Overall Study
    Formoterol 12 First     Formoterol 24 First  
STARTED     6     6  
COMPLETED     4     6  
NOT COMPLETED     2     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
All Participants A single dose of 12 mcg and 24 mcg, on separate days, of formoterol were given.

Baseline Measures
    All Participants  
Number of Participants  
[units: participants]
 		  12  
Age  
[units: participants]
 		 
<=18 years     0  
Between 18 and 65 years     12  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation 		  36.8  ± 14.5  
Gender  
[units: participants]
 		 
Female     7  
Male     5  
Region of Enrollment  
[units: participants]
 		 
United States     12  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Post-dose PC20   [ Time Frame: 3-7 days after visits 1 and 2 ]
  Show Outcome Measure 1

2.  Secondary:   FEV1   [ Time Frame: 1 hour after dose ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Show More Information